Pinnacle Wealth Planning Services’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.98K	Buy	87 +19	+28%	+$1.04K	﹤0.01%	2293
2026 Q1	$3.84K	Buy	68 +5	+8%	+$292	﹤0.01%	2314
2025 Q4	$3.74K	Buy	+63	New	+$3.43K	﹤0.01%	2349
2021 Q1	–	Sell	-1,322	Closed	-$116K	–	557
2020 Q4	$116K	Buy	+1,322	New	+$105K	0.03%	414

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Pinnacle Wealth Planning Services's BMRN Position: Q2 2026 in Review

Pinnacle Wealth Planning Services increased its BioMarin Pharmaceuticals (BMRN) stake by 28% in Q2 2026, buying an estimated $1.04K and bringing the position to 87 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Pinnacle Wealth Planning Services first reported a position in BMRN in Q4 2020 and has held it in 4 quarters since. The position peaked at $116K in Q4 2020. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Pinnacle Wealth Planning Services held 87 shares of BioMarin Pharmaceuticals worth $4.98K as of Q2 2026.
Pinnacle Wealth Planning Services bought 19 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
BioMarin Pharmaceuticals made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q2 2026, its #2293 holding.
Pinnacle Wealth Planning Services first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 4 quarters since.
Pinnacle Wealth Planning Services's BioMarin Pharmaceuticals position peaked at $116K in Q4 2020.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q2 2026, filed 7 Aug 2026.